Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Clinical trial NCT07192237 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07192237
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-27
- Primary completion
- 2030-10-12
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.